17703-02-5

Basic information

• Product Name: benzo[a]pyrido[2,3-c]phenazine
• Synonyms: Benzo[a]pyrido[2,3-c]phenazine
• CAS NO: 17703-02-5
• Molecular Formula: C₁₉H₁₁N₃
• Molecular Weight: 281.3107
• Mol File: 17703-02-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 558.4°C at 760 mmHg
• Flash Point: 262.3°C
• Density: 1.368g/cm³
• Vapor Pressure: 6.26E-12mmHg at 25°C
• Refractive Index: 1.85
• CAS DataBase Reference: benzo[a]pyrido[2,3-c]phenazine(CAS DataBase Reference)
• NIST Chemistry Reference: benzo[a]pyrido[2,3-c]phenazine(17703-02-5)
• EPA Substance Registry System: benzo[a]pyrido[2,3-c]phenazine(17703-02-5)

Safety Data

• Hazardous Substances Data: 17703-02-5(Hazardous Substances Data)

Upstream product

• 230-27-3 7,8-benzoquinoline 
• 65938-98-9 benzoquinoline-5,6-dione 
• 95-54-5 1,2-diamino-benzene 

Relevant articles and documents

Organometallic Ru(II) Photosensitizers Derived from "-Expansive Cyclometalating Ligands: Surprising Theranostic PDT Effects

The purpose of the present study was to investigate the influence of "-expansive cyclometalating ligands on the photophysical and photobiological properties of organometallic Ru(II) compounds. Four compounds with increasing " conjugation on the cyclometalating ligand were prepared, and their structures were confirmed by HPLC, 1D and 2D 1H NMR, and mass spectrometry. The properties of these compounds differed substantially from their Ru(II) polypyridyl counterparts. Namely, they were characterized by red-shifted absorption, very weak to no room temperature phosphorescence, extremely short phosphorescence state lifetimes (50 values = 1-2 μM), in agreement with what has traditionally been observed for Ru(II) compounds derived from small C^N ligands. Surprisingly, the complex derived from the most "-expansive cyclometalating ligand exhibited no cytotoxicity in the dark (EC50 > 300 μM) but was phototoxic to cells in the nanomolar regime. Exceptionally large phototherapeutic margins, exceeding 3 orders of magnitude in some cases, were accompanied by bright ligand-centered intracellular fluorescence in cancer cells. Thus, Ru(II) organometallic systems derived from "-expansive cyclometalating ligands, such 4,9,16-triazadibenzo[a,c]napthacene (pbpn), represent the first class of potent light-responsive Ru(II) cyclometalating agents with theranostic potential.